Efficacy and Safety of the CollaRx Bupivacaine Implant Compared to the ON-Q Painbuster Following Abdominal Hysterectomy
Condition: Pain, Postoperative
MeSH terms: Pain, Postoperative
Intervention: Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant); ON-Q PainBuster Post-op Pain relief System
Intervention description: The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride; 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])
Intervention MeSH terms: Bupivacaine
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 27.0
Sex: Female
Minimum age: 18 Years
Maximum age: 75 Years
Healthy volunteers: No
Keywords: Abdominal Hysterectomy; Postoperative pain

Summary:

      The purpose of this study is to determine whether the CollaRx Bupivacaine Implant is safe and
      effective in reducing the amount of narcotic pain medication needed to control pain during
      the first 96 hours after abdominal hysterectomy when compared to the ON-Q PainBuster Post-op
      Pain Relief System.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Must be a woman who is ≥ 18 and ≤ 75 years of age.

          -  Has a body mass index (BMI) > 19 and < 40 kg/m2.

          -  Has planned an elective total abdominal hysterectomy for reasons other than
             malignancies (such as uterine adenocarcinoma, cervical cancer or leiomyosarcoma) to be
             performed according to standard surgical technique using a standard incision and under
             general anesthesia with the following caveats:

               -  Laparoscopic procedures or supraumbilical or Maylard incisions will not be
                  allowed.

               -  A nonlaparoscopic incision for benign nonhysterectomy gynecological procedures
                  (such as myomectomy or adnexal surgery) is acceptable if the surgical indication
                  is not to treat pelvic pain.

               -  No concomitant vaginal procedures such as anterior and posterior colporrhaphy
                  (A&P repairs) are allowed. An abdominal urethropexy and an incidental
                  appendectomy will be allowed.

          -  Has a risk classification of I, II or III according to the American Society of
             Anesthesiologists (ASA).

          -  Is nonpregnant (negative pregnancy test at Screening and Day 0 before surgery) and
             nonlactating.

          -  Is free of other physical or mental conditions that, in the opinion of the
             Investigator, may confound quantification of postoperative pain resulting from the
             abdominal hysterectomy.

          -  Has the ability to read, understand and comply with the study procedures and the use
             of the pain scales; is deemed capable of operating a patient controlled analgesia
             (PCA) device; and is able to communicate meaningfully with the study staff.

          -  Must voluntarily sign and date an informed consent form (ICF), approved by an
             Institutional Review Board (IRB), prior to the conduct of any study specific
             procedures.

          -  Must be able to fluently speak and understand English and be able to provide
             meaningful written informed consent for the study.

        Exclusion Criteria:

          -  Has known hypersensitivity to amide local anesthetics, opioids, bovine products or to
             inactive ingredients of the test article or reference product.

          -  Has cardiac arrhythmias or atrioventricular (AV) conduction disorders.

          -  Concomitantly uses other amide local anesthetics.

          -  Concomitantly uses antiarrhythmics (eg, amiodarone), propranolol or strong/moderate
             cytochrome P450 (CYP) 3A4 inhibitors or inducers (eg, macrolide antibiotics and
             grapefruit juice).

          -  Has used long acting analgesics within 24 hours of surgery. Short acting analgesics
             such as acetaminophen may be used on the day of surgery but are subject to
             preoperative restrictions for oral intake.

          -  Has used aspirin or aspirin containing products within 7 days of surgery. Aspirin at a
             dose of ≤ 325 mg is allowed for cardiovascular prophylaxis if the patient has been on
             a stable dose regimen for ≥ 30 days prior to Screening.

          -  Has undergone major surgery within 3 months of the scheduled hysterectomy.

          -  Requires the use of Seprafilm® or other absorbable adhesion barriers for the scheduled
             hysterectomy.

          -  Requires any additional surgical procedures either related or unrelated to the
             abdominal hysterectomy during the same hospitalization (except for the specific
             allowed procedures noted in the Inclusion Criteria).

          -  Is required to receive neuraxial (spinal or epidural) opioid analgesics during the
             surgery.

          -  Has known or suspected history of alcohol or drug abuse or misuse within 3 years of
             Screening or evidence of tolerance or physical dependency on opioid analgesics or
             sedative hypnotic medications.

          -  Has used opioids or tramadol on an extended daily basis (> 7 days) prior to surgery.
             Patients who, in the Investigator's opinion, are developing opioid tolerance are to be
             excluded.